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Psoriasis is a T-cell mediated disease that involves IL-23/Th17 and IL-12/Th1 axes. Ustekinumab, a fully 
human monoclonal antibody targeting the p40 subunit of both IL-12 and IL-23, has proven to be efficient 
and safe for treating patients with psoriasis. Yet, there have been no reports with human skin/blood samples 
that would elucidate the molecular mechanisms by which ustekinumab calms psoriasis skin lesions. To 
investigate the efficacy and molecular pathway (RORC, t-BOX and GATA) of ustekinumab in treating 
patients with psoriasis skin lesions. A total of 30 patients with psoriasis were randomized into placebo 
group and treatment group. PASI of each patient was calculated at 0, 12 and 24 weeks post-treatment. 
The mRNA levels of RORC, t-BOX and GATA in peripheral blood mononuclear cells separated from 
patients’ whole blood were analyzed using qPCR. Decreased mRNA of RORC, t-BOX and GATA were 
observed after continuous injections, indicating that ustekinumab exerts its effect by interacting with 
these molecules; while no significant difference in foxp3 mRNA levels were found between placebo 
group and treatment group.
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INTRODUCTION
Psoriasis is a chronic, inflammatory and proliferative 
skin disease, characterized by impaired differentiation, 
overactive hyperproliferation of epidermal keratinocytes, 
disturbed keratinization and aberrant activation of T 
lymphocytes. It involves complicated pro-inflammatory 
cytokine networks, where Th1/Th2 homeostasis, Th17/
Treg balance, IL-23/Th17 axis and IL-12/Th1 axis have 
shown to have important roles (Deng, Chang, Lu, 2016; 
Harden, Krueger, Bowcock, 2015). IL-12 and IL-23 have 
shown to be involved in the development of Th1 and Th17 
immune responses in psoriasis (Lee et al., 2004; Yawalkar 
et al., 2009), and thus have become potential targets for 
treating patients with psoriasis.
Ustekinumab, a new class of anti-cytokine drugs, is 
a human monoclonal antibody that targets the p40 subunit 
of both IL-12 and IL-23, and thus directly neutralizes 
their biological activity, and decreases the immune cell 
activation properties of IL-12 and IL-23. Several clinical 
trials have demonstrated the superior clinical efficacy and 
safety of ustekinumab in the treatment of moderate-to-
severe psoriasis and psoriatic arthritis (Kavanaugh et al., 
2014; Nast et al., 2015; Strober et al., 2016; Tsai et al., 
2011) with sustained efficacy after 3 years of treatment 
(Kimball et al., 2012). Nevertheless, according to PASI-
75 (PASI: Psoriasis area-and-severity index) its efficiency 
was lower than in IL-17 pathway blockers, for example, 
secukinumab (Tan, Griffiths, 2016).
Ustekinumab stimulates peripheral blood monocytes 
(PBMC) so as to modulate cytokines (Nograles et al., 2008; 
Reddy et al., 2010). However, to our knowledge, there have 
been no reports with human skin/blood samples elucidating 
the pathway by which ustekinumab modulates full blood 
white cells thus influencing human keratinocytes’ cellular 
processes. There are also no reports on how ustekinumab 
achieves its efficacy in the treatment of psoriasis and/or 
presents distinctive properties from other biologic agents.
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Retinoic acid-related orphan receptor γ (RORγ, 
the human form: RORC) is the key transcription factor 
involved in IL-17-producing cells (Zhang et al., 2015). 
The inhibition of RORC has shown to be effective in 
decreasing psoriatic lesions (Rizvi, Chaudhari, Syed, 
2015; Takaishi et al., 2017). Furthermore, transcription 
factor forkhead box P3 (foxp3) is a marked factor 
of regulatory T cells (Treg) development (Williams, 
Rudensky, 2007) and its interaction with RORC can 
inhibit IL-17 (Ichiyama et al., 2008). T-box family of 
transcription factors is a master determinant of Th1 lineage 
(Szabo et al., 2000). GATA-3 encodes a protein belonging 
to the Th2-specific transcription factors, promoting Th2 
differentiation (Lantelme et al., 2001) and inducing Th2 
cytokine production in an analogous way to T-box (Lee 
et al., 2000). Dominance of Th1 over Th2 is related with 
psoriasis (Zhu et al., 2010). 
Our aim was to verify our assumption that 
ustekinumab has longer sustainment because it can 
interact with RORC, T-box, foxp3 and GATA. The real-
time qPCR was carried out to detect the changes it caused 
on mRNA levels in patients treated with placebo (P group) 
and ustekinumab-treated patients (U group).
MATERIAL AND METHODS
Patients, inclusion and exclusion criteria
Patients with psoriasis were enrolled in the 2nd 
Affiliated Hospital, School of Medicine, Zhejiang 
University, Hangzhou, China. The period of the study 
was 30 months. 
The inclusion criteria were the following: (1) 
patients with moderate to severe plaque psoriasis; (2) 
patients between 18-65 years old, diagnosed with plaque 
psoriasis for at least 6 months before the beginning of the 
study; (3) patients with PASI > 12, and skin lesion area 
takes up > 10% of total body surface area; (4) patients with 
no history of biologic agents treatment. 
Exclusion standards were: (1) patients with 
erythrodermic psoriasis or psoriatic arthritis or psoriasis 
pustulosa or psoriasis guttate; (2) patients with severe 
and uncontrollable local or systematic acute/chronic 
infections; (3) patients with active or potential tuberculosis 
or asthma; (4) patients with malignancy history; (5) 
patients with other severe systematic disease; (6) patients 
who were prescribed with drugs or biologic agent; (7) 
patients who received immunosuppressor within 1 month 
or (8) psoriasis systematic treatment or phototherapy 
within 1 month or (9) psoriasis topical agents within 2 
weeks. 
The study was approved by the Medical Ethics 
Committee of the 2nd Affiliated Hospital, School of 
Medicine, Zhejiang University, Hangzhou, China 
(approval number is 2009-32).
Treatment
Patients were treated with ustekinumab according 
to previously described approach (Tsai, Ho, 2011). In the 
present study, we designed a crossover tests based on the 
ethics (Figure 1). Patient in the treatment group (U group) 
were subcutaneously injected with 45 mg ustekinumab 
at weeks 0, 4, 16, and 0.9% NaCl at week 12; while the 
placebo group (P group) was subcutaneously injected with 
0.9% NaCl at weeks 0 and 4, and 45 mg ustekinumab at 
weeks 12 and 16.
Efficacy assessment
PASI was adopted for the efficacy assessment; 
when PASI improvement rate reached or exceeded 75% 
(PASI-75), the treatment was considered effective. PASI 
of each patient was calculated at weeks 0, 12 and 24, 
respectively; in weeks 0 and 12, PASI was measured 
before administration of NaCl or ustekinumab.
Sample collection
Whole blood samples were collected at weeks 0, 12 
and 24 post- treatment. 
FIGURE 1 - Flowchart of the study. USTK: Ustekinumab. 
P Group: placebo group. U Group: Ustekinumab group.
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Whole blood red blood cell lysis buffer 
preparation
10x stock solution was prepared consisting of 89.9 g 
NH4Cl, 10.0 g KHCO3, 370.0 mg tetrasodium EDTA, 
following pH adjustment to 7.3. The solution was then 
dissolved in 1 liter of pure water.
RNA extraction and real-time quantitive PCR
Red blood cells in whole blood samples were 
dissolved by whole blood red blood cell lysis buffer. Then 
total RNA was isolated from patients’ peripheral leukocytes 
using invitrogenTM TrizolTM. cDNA was prepared using 
Superscript II Reverse Transcriptase (Invitrogen). Gene 
expression was determined using SYBR green PCR mix 
(Roche) and 10 ng template. Real-time PCR analysis was 
performed using ABI StepOne Plus instrument under the 
following amplification conditions: 5 s at 95 °C, followed by 
45 cycles of 30 s at 60 °C (RORC); 5 s at 95 °C, followed by 
45 cycles of 30 s at 60 °C (FOXP3); 5 s at 95 °C, followed 
by 45 cycles of 30 s at 60 °C (T-box21); 5 s at 95 °C, 
followed by 45 cycles of 30 s at 60 °C (GATA). Primers 
for RORC (5’-CAATGGAAGTGGTGCTGGTTAG-3’, 
5 ’ - G G G A G T G G G A G A A G T C A A A G AT- 3 ’ ) , 
FOXP3 (5’-ATTCCCAGAGTTCCTCCACAAC-3’, 
5 ’ - A T T G A G T G T C C G C T G C T T C T - 3 ’ ) , 
T-box  (5 ’ -GCCCCTTCTCCTTTTGATAA-3’ , 
5 ’ -CGGTGTCCTCCAACCTAATAAC-3’)  and 
GATA (5’-AGACCACCACAACCACACTCT-3’, 
5’-GATGCCTTCCTTCTTCATAGTCA-3’) were 
designed using Beacon designer (Premier Software). 
Transc r ip t  express ion  was  normal ized  to  the 
GAPDH house-keeping gene and represented as 
either 2-△△CT (2-△△CT=2-△CT (gene of interest/average 
[2-△CT (house-keeping gene)]) in the case of p35 or p40 
expression.
Statistics and graph making
Differences between every two groups were 
evaluated with unpaired two-tail t-test. PASI75 rates 
(percentages of PASI improvement rate reaching 
or exceeding 75% of P and U groups, PASI75%) 
were compared between P and U groups using 
kappa test. PASI improvement rate (W12vsW0 or 
W24vsW0)=[PASI(Week0)-PASI(Week12 or Week24)]/ 
PASI(Week0). *p<0.05, **p<0.005, ***p<0.0001. Data 
analysis and graphs were performed using Prism software 
(GraphPad software, Inc.). In all the graphs, ● stands for 
P group, and ▲ stands for U group.
RESULTS
A total of 30 patients with psoriasis were enrolled 
(age: 18-60 years old; 7 females and 23 males). Initial PASI 
ranged from 12.2 to 55.6. The average PASI was 22.86. The 
standard error of mean (SEM) of PASI was 1.96. Patients 
were double-blindly and randomly divided into placebo 
group (P group, n=16, average PASI=23.06, SEM of PASI= 
3.40) and ustekinumab-treated group (U group, n=14, 
average PASI=22.64, SEM of PASI=1.80). One patient 
did not sign the informal consent for the mRNA level test, 
therefore his mRNA data were excluded from the study. 
Maximum drug efficacy can be obtained within 2 
injections of ustekinumab 
To demonstrate the clinical efficacy of ustekinumab, 
we investigated the intergroup and intragroup comparisons 
of individual’s PASI at 3 different time-points (Figure 2). 
Briefly, a significant decrease in PASI was observed in 
U group at week 12 compared to P group. In addition, in 
the U group, PASI decreased significantly at weeks 12 
and 24, compared to week 0; nevertheless, no significant 
difference was found between weeks 12 and 24. Besides, 
in the P group, PASI decreased significantly at week 24 
compared to week 0.
With the reference to PASI-75 rate, higher PASI-75 
rate was found in the U group compared to P group, and 
FIGURE 2 - Intragroup and intergroup comparisons of PASI in 
different timepoints. There are highly significant differences 
between P group and U group at Week 12. There are significant 
differences in P group between week 0 and week 24, in U group 
between weeks 0 and 12, 24 respectively. ● stands for P group, 
and ▲ stands for U group.
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this was also verified by kappa test (Table I); significant 
differences were found at week 12 compared to week 0 
(p=0.001013), while no significance was detected between 
week 24 and week 0 (p=0.74), indicating no significant 
improvement in PASI-75 rate at week 24.
To sum up, the results indicated that ustekinumab 
is effective in treating psoriasis skin lesions; ustekinumab 
can reach the maximum efficiency after 2 injections, and 
then its treatment effect remains constant overtime.
Multiple injections of ustekinumab suppresses 
RORC, t-BOX, GATA but not foxp3 mRNA 
With reference to RORC mRNA, a significant 
difference between week 0 and week 24 was found 
in group U (Figure 3a), while in P group there were 
no significant differences at different time-points, and 
between U group and P group. Furthermore, a significant 
difference in t-BOX and GATA mRNA levels between 
TABLE I - Kappa tests of PASI of P group and U group, comparing week 12 to week 0, week 24 to week 0 respectively
W12 vs. W0 W24 vs. W0
PASI-75 (n) PASI improvement 
rate≤75% (n)
PASI-75 (n) PASI improvement 
rate≤75%  (n)
P group 2 14 13 3
U group 10 4 12 2
P value – 0.001** – 0.74
FIGURE 3 - Intergroup and intragroup comparisons of RORC (a), t-BOX (b), foxp3 (c) and GATA (d) mRNA levels at weeks 0, 
12 and 24. ● stands for P group, and ▲ stands for U group.
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week 24 and weeks 0 or 12 were found in group U (Figure 
3b and 3d, respectively). Hence, this raises a question if 
the expressions of GATA and t-BOX are parallel one to 
another. In addition, no significant difference in foxp3 
mRNA levels were found between groups (Figure 3c). 
To sum up, our data suggested that ustekinumab 
suppresses RORC, t-BOX and GATA. In addition, the 
maximum suppression effect of RORC can be achieved 
after 3 injections, while the maximum suppression effect of 
both t-BOX and GATA can be achieved after 2 injections. 
Also, it seems that ustekinumab has no effect on foxp3 
expression.
DISCUSSION 
Great progress has been made in declaring different 
roles of different T cell subsets. Among these cell types, 
T helper 17 (Th17) and other IL-17–producing cells, 
notably γδ T cells and CD8+ T cells, have been in the 
center of attention. IL-23/Th17 axis mainly controls 
the proinflammatory loop in psoriatic plaques (Diani, 
Altomare, Reali, 2016; Kryczek et al., 2008). Based on 
our PASI assessment, there were significant differences 
between P group and U group at week 12 post-treatment. 
There were significant differences in P group between 
weeks 0 and 24, in U group between weeks 0, 12, 
and 24 respectively. These results indicated that two 
injections of ustekinumab were sufficient for maximal 
efficacy. According to the instructions, in case of 
moderate to severe plaque psoriasis and active psoriatic 
arthritis, the recommended dose of ustekinumab is 45 
mg administered at week(s) 0 and 4, and then every 12 
weeks. Therefore, we hypothesized that the third and 
following injections might intensify ustekinumab’s effect 
or prolong its efficacy.
RORC is the key transcription factor involved in the 
production and regulation of IL-17 from Th17, γδT cells, 
innate lymphoid (ILCs), lymphoid tissue inducer (LTi) 
cells (Fauber, Magnuson, 2014; Isono, Fujita-Sato, Ito, 
2014; Yang et al., 2014; Zhang, Luo, 2015) and IL-22 and 
IL-23 from Th17 (Smith et al., 2016). Various antibodies, 
both upstream and downstream of RORC, specifically 
anti-IL-12p40 and anti-IL-17A agents have shown to be 
efficacious in the treatment of psoriasis (Rizvi, Chaudhari, 
2015). Takaishi et al. (2017) have described attenuation of 
psoriasis-like lesions in two independent psoriasis mouse 
models after oral administration of RORγt (a specific 
transcript of the RORC gene) antagonist and suggested 
that this effect was based on neutralization of IL-17-
producing cells. Our data showed that ustekinumab has an 
RORC-suppressing effect during long-term use, which is 
helpful in improving psoriatic skin lesions, and probably 
associated with its anti-IL12/23 effect.
Foxp3 is one of the most specific markers used to 
identify Regulatory T Cell (Tregs). Overexpression of 
Foxp3 is required to maintain function and lineage identity 
of mature peripheral Tregs (Williams and Rudensky, 
2007). Upregulated Foxp3 initially binds to RORγt, 
thereby reducing IL-17A expression and inhibiting 
RORγt-mediated IL-17A promoter activity (Ichiyama, 
Yoshida, 2008). Etanercept, a TNF inhibitor, can induce 
transcriptional levels of Foxp3, STAT3 and STAT4 mRNA 
in responding patients with psoriasis (Quaglino et al., 
2011). Adalimumab, also a TNF-inhibiting medication 
expands functional Foxp3+ Tregs via binding monocyte 
membrane TNF (Nguyen et al., 2016). Accordingly, foxp3 
is upregulated by the neutralization of TNF. Our results 
indicated that ustekinumab didn’t suppress or enhance 
foxp3 mRNA levels, at least not within 3 injections. 
Probably, ustekinumab decreases psoriatic skin lesions 
independently from TNF pathway. On the other hand, it 
can be used as a substitute for anti-TNF agents in patients 
not responding to anti-TNF agents, since psoriasis has 
multiple pathogenic mechanisms.
As  the  ups t r eam of  the  IL-17  d r ives  the 
proinflammatory loop, Th1 produces interferon-γ (IFN-γ) 
favoring the recruitment and expansion of IL-17-producing 
cells (Diani, Altomare, 2016; Kryczek, Bruce, 2008). T-box 
family of transcription factors is a main determinant of 
Th1 lineage (Szabo, Kim, 2000). Memory CD4+ T cells 
express a high level of T-box. Pre-mobilization of T-box 
into nuclei might have more important roles at early time 
points for rapid responses of memory T cells (Yu et al., 
2014). Expression of the human T-box correlates with 
IFN-γ expression in Th1 and natural killer cells (Yu, Zhang, 
2014), suggesting that this gene is initiating Th1 lineage 
development from naive Th precursor cells. T-box sustains 
the effector function of CD8+ T cells through regulation 
of CD8+ T cell proliferation, suppressed expression of 
inhibitory receptors such as PD-1, and promotion of IFN-γ 
and perforin secretion (Lazarevic, Glimcher, 2011). Our 
data demonstrated that ustekinumab can inhibit T-box 
expression. Combining current discoveries, it needs further 
investigation whether ustekinumab can affect nuclei-located 
T-box.
GATA-3 encodes a protein that belongs to the 
Th2-specific transcription factors, promoting Th2 
differentiation (Lantelme et al., 2001) and inducing Th2 
cytokine production in an analogous way to T-box (Lee, 
Takemoto, 2000). Regulation of Th1/Th2 balance can be 
mediated by the level of T-box and GATA-3 (Park et al., 
2009). The expression of GATA is, however, markedly 
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up-regulated in cells differentiating along the Th2 lineage, 
and is down-regulated in cells differentiating along the 
Th1 pathway (Frisullo et al., 2006). Compared to healthy 
controls, a significantly higher expression of T-box 
mRNA and lower expression of GATA-3 mRNA were 
tested in PBMCs of psoriatic patients, and consequently, 
a much higher T-box/GATA-3 ratio was found in patients 
than in controls (Zhu et al., 2010). The high T-box and 
low GATA-3 expression in PBMCs and lesioned skin 
of psoriatic patients indicates a skew towards the Th1 
pathway of T-helper cell activation. T-box and GATA-3 
might be regulator genes in psoriasis via the Th1/Th2 
balance. Furthermore, our data showed that ustekinumab 
suppressed GATA expression. From this perspective, it 
antagonizes the treatment of psoriasis. 
To sum up, from the aspect of molecular mechanism, 
ustekinumab can be seen as a double-edged sword in 
psoriasis treatment. On the positive side, it suppresses the 
expression of RORC and T-box. On the negative side, it 
suppresses the expression of GATA and has no impact on 
foxp3. The effectiveness of Ustekinumab independent of 
TNF pathway reveals its potential effect for patients not 
responding to anti-TNF agents. Screening out patients 
responding to ustekinumab is the key to making best of 
the equilibrium between positive and negative sides and 
to obtaining the most ideal treatment outcome. Future 
randomized clinical trials are necessary to verify these 
findings. 
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